The Innovation Reduction Act With Allan Shaw

Source: Cytiva

Allan Shaw posits that the Inflation Reduction Act (IRA) will stifle momentum in the biopharma industry and suggests its impact will ultimately cost patients and payers more. Tune in to learn why.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online